Aerie Pharmaceuticals ^{Priced, Nasdaq: AERI}

Clinical-stage biotech developing treatments for glaucoma.

Industry: Health Care

First Day Return: +6.1%

Industry: Health Care

AERI

Clinical-stage biotech developing treatments for glaucoma.

more less

IPO News for Aerie Pharmaceuticals

Eye drop IPO Inotek Pharmaceuticals prices IPO at $6 per share 02/18/15
Blindness biotech blinks: Inotek Pharmaceuticals slashes proposed IPO valuation by 50% 02/17/15
Rare eye disease biotech Applied Genetic Tech sets terms for $50 million IPO 03/12/14

IPO Data
IPO File Date	09/17/2013
Offer Price	$10.00
Price Range $12.00 - $14.00
Offer Shares (mm)	6.7
Deal Size ($mm)	$67
Lock-Up Date	IPO Pro Only
Street Research	IPO Pro Only

IPO Data
IPO Date	10/24/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$67
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Bedminster, NJ, United States
Founded	2005
Employees at IPO	23
Website www.aeriepharma.com

IPO News for Aerie Pharmaceuticals

Aerie Pharmaceuticals (AERI) Performance